Association of microRNA-27a rs895819 polymorphism with the risk of cancer: an updated meta-analysis.
MiR-27a rs895819 polymorphism is considered as a tumor- related susceptibility gene. Previous meta-analyses evaluated the association the association between miR-27a rs895819 and cancer risk, but the results were inconsistent. The present meta-analysis was carried out to better estimate the correlation of rs895819 and cancer susceptibility. We searched several databases to identify relevant studies, including PubMed, EMBASE and the Cochrane Controlled Trials Register. The odds ratios (ORs) with 95% confidence intervals (CIs) were used to estimate the association between miR-27a rs895819 and cancer risk. The overall analysis showed the miR-27a rs895819 was not associated with cancer susceptibility in all models (dominant model: OR=1.02, 95% CI:0.94-1.10, p=0.632; recessive model :OR=1.05, 95% CI: 0.92-1.76, p=0.474; homozygote model: OR=1.06, 95% CI: 0.91-1.23, p=0.439; heterozygote model: OR=1.00, 95% CI: 0.93-1.08, p=0.934; and allele model: OR=1.02, 95% CI: 0.96-1.09, p=0.486). Interestingly, rs895819 A > G was significantly associated with colorectal cancer risk in recessive model (OR=1.54, 95% CI: 1.29-1.83, p<0.001), homozygote model (OR=1.59, 95% CI: 1.31-1.92, p<0.001), and allele model (OR=1.22, 95% CI: 1.10-1.34, p<0.001). In addition, rs895819 polymorphism was correlated with increased risk of breast cancer in the recessive model (OR=0.81, 95% CI: 0.66-1.00, p=0.046) and allele model (OR=0.89, 95% CI: 0.80-0.98, p=0.021). Our results suggested that rs895819 polymorphism was correlated with increased risk of colorectal cancer and breast cancer, but not all types of cancer.